8-K: Catheter Precision Reports Third Quarter Results, Highlights Commercial and Clinical Progress

Catheter Precision announced its third quarter financial results and provided an operational update, noting progress in commercial activities, clinical studies, and regulatory approvals.

Summary

• Catheter Precision reported its financial results for the quarter ending September 30, 2024, with total assets of $26.7 million and shareholders' equity of $12.8 million.
• The company's sales revenue for the quarter was approximately $96,000, and $271,000 for the nine-month period.
• The net loss for the quarter was $4.1 million, including $1.7 million in non-cash charges, and the net loss for the nine-month period was $11.0 million, including $4.4 million in non-cash charges.
• The company's cash position at the end of the quarter was $1.3 million, but they received $4.9 million in gross proceeds from warrant exercises in October.
• Catheter Precision has 87 hospitals in its pipeline of potential customers, with 32 institutions actively evaluating their products.
• The company is progressing with VIVO procedures in multiple European countries and anticipates CE Mark approval for LockeT by the end of the first quarter of 2025, with a launch in the EU expected in the second quarter of 2025.
• Clinical studies for both LockeT and VIVO are ongoing, with several publications and presentations highlighting positive results.
• The company is planning additional studies for LockeT focusing on different procedure types and catheter sizes, and VIVO studies are evaluating accuracy and improved procedural workflow.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is positive progress in clinical trials, regulatory approvals, and commercial activities, the company's financial performance is weak, with significant losses and low revenue. The need for additional financing also introduces uncertainty.

Positives

• The company has a growing pipeline of potential customers, with 87 hospitals expressing interest.
• There is significant progress in both the US and Europe, with VIVO procedures scheduled or continuing in multiple countries.
• The company is making headway with regulatory approvals, with the CE Mark for LockeT expected in early 2025.
• Clinical studies for both LockeT and VIVO are showing positive results, with several publications and presentations.
• The company has a strong clinical trial program and publication plan in place.
• The company has secured additional funding through the exercise of outstanding warrants.

Negatives

• The company reported a net loss of $4.1 million for the third quarter of 2024.
• The company's cash position at the end of the quarter was $1.3 million.
• Sales revenues for the quarter were relatively low at approximately $96,000.
• The company's net loss for the nine months ended September 30, 2024, was approximately $11.0 million.

Risks

• The company's expectations regarding clinical trial results and timelines may not materialize.
• The company may not have sufficient liquidity to fund operations without additional financing or strategic transactions.
• The company's ability to reach profitability depends on achieving product expansion and growth goals.
• The company's research and development efforts may depend on agreements with corporate collaborators.
• The company faces risks related to joint marketing agreements, royalty agreements, and potential disruptions in information technology systems.
• The company may face challenges related to litigation, acquisitions, and the ability to attract and retain qualified personnel.
• The company has identified material weaknesses in its internal controls and disclosure controls.
• The company's revenues may depend on customers' receipt of adequate reimbursement from private insurers and government-sponsored healthcare programs.
• The company faces intense competition in the medical device industry.
• The company's future operating results depend on its ability to obtain components in sufficient quantities on commercially reasonable terms.
• The company's products may be subject to recalls, revocations, or suspensions after receiving regulatory approval.
• Changes in trade policies and tariffs could negatively impact the company's average selling prices and operating results.
• The COVID-19 pandemic, supply chain disruptions, and volatility in the stock markets and the U.S. economy could amplify the risks and uncertainties faced by the company.

Future Outlook

The company anticipates positive sales revenue results in the coming quarters and expects numerous publications from ongoing clinical studies to demonstrate the effectiveness of their products. They also believe the ventricular market could grow significantly, and they intend to be a meaningful player in the electrophysiology market.

Management Comments

• David Jenkins, CEO of Catheter Precision, stated that he is excited to see both the clinical data and the commercial execution coming together.
• The CEO believes that the number of studies and publications should provide evidence to the medical community of the effectiveness and necessity of both their LockeT and VIVO product lines.
• The CEO noted that the new sales and clinical team have been on board for their first full quarter, and they are seeing the results of their investment coming through on the pipeline.
• The CEO mentioned that the majority of the net loss for the third quarter relates to expenses for commercial activities.
• The CEO expressed confidence in the company's commercial execution and hopes for positive sales revenue results in the coming quarters.
• The CEO stated that the company has a strong clinical trial program and publication plan in place.
• The CEO believes that the ventricular market could one day be as large as the atrial fib market.

Industry Context

The announcement highlights Catheter Precision's efforts to establish itself in the electrophysiology market, which is experiencing growth and innovation. The company's focus on ventricular arrhythmias and the development of tools like VIVO aligns with the industry's need for improved diagnostic and treatment options. The mention of other companies starting trials for ablation catheters for VT confirms the market opportunity for VIVO.

Comparison to Industry Standards

• While specific revenue figures for comparable companies are not provided, the reported revenue of $96,000 for the quarter and $271,000 for the nine months is low compared to established medical device companies.
• The company's focus on electrophysiology and specific products like VIVO and LockeT positions them in a niche market, but they face competition from larger players like Medtronic, Boston Scientific, and Abbott, who also have products in the cardiac rhythm management space.
• The company's clinical trial program and publication plan are consistent with industry standards for demonstrating the efficacy and safety of medical devices.
• The company's efforts to obtain CE Mark for LockeT and expand into the European market are typical for medical device companies seeking global growth.
• The company's focus on ventricular tachycardia is a specific area of interest, as the atrial fibrillation market is more established, and the company believes the ventricular market could grow to a similar size.

Stakeholder Impact

• Shareholders may be concerned about the company's significant net losses and low revenue.
• Employees may be impacted by the company's financial situation and potential need for additional financing.
• Customers (hospitals and physicians) may be interested in the company's innovative products and clinical data.
• Suppliers may be affected by the company's ability to obtain components and manage its supply chain.
• Creditors may be concerned about the company's financial stability and ability to repay debts.

Next Steps

• The company plans to complete the CE Mark process for LockeT and launch the product in the EU in the second quarter of 2025.
• The company intends to continue ongoing clinical studies for both LockeT and VIVO.
• The company plans to publish data from ongoing and completed clinical studies throughout 2025.
• The company will continue to expand its commercial activities and pipeline of potential customers.
• The company will continue to invest in its clinical trial program and publication plan.

Key Dates

Keywords

electrophysiology, medical devices, cardiac arrhythmias, VIVO, LockeT, clinical studies, CE Mark, hemostasis, ventricular tachycardia, sales revenue